CUPERTINO, Calif., April 27, 2021 /PRNewswire/ -- DURECT
Corporation (Nasdaq: DRRX) today announced that it will report
its first quarter 2021 financial results and host a conference call
after the market close on Tuesday, May 4,
2021.
Tuesday, May 4
@ 4:30pm Eastern Time / 1:30 p.m. Pacific
Time
|
Toll
Free:
|
877-407-0784
|
International:
|
201-689-8560
|
Conference
ID:
|
13718713
|
Webcast:
|
http://public.viavid.com/index.php?id=144373
|
About DURECT Corporation
DURECT is a
biopharmaceutical company committed to transforming the treatment
of acute organ injury and chronic liver diseases by advancing novel
and potentially lifesaving therapies based on its endogenous
epigenetic regulator program. DUR-928, the company's lead drug
candidate is in clinical development for the potential treatment of
alcohol-associated hepatitis (AH) for which FDA has granted a Fast
Track Designation. The Company is conducting a double-blind,
placebo-controlled Phase 2b clinical
trial called AHFIRM, evaluating DUR-928's life saving potential
compared to the current standard of care in patients with severe
AH. Non-alcoholic steatohepatitis (NASH) is also being
explored. In addition, POSIMIR® (bupivacaine
solution) for infiltration use, a non-opioid analgesic utilizing
the innovative SABER® platform technology, is now
FDA-approved. Full prescribing information about POSIMIR, including
the Boxed Warning, can be found at www.posimir.com. For more
information about DURECT, please visit www.durect.com and follow us
on Twitter https://twitter.com/DURECTCorp.
DURECT Forward-Looking Statement
The statements in this press release regarding the potential for
DUR-928 to treat patients with AH, NASH, and other diseases,
multiple acute organ injury, ongoing and planned clinical trials of
DUR-928, and the commercial potential of POSIMIR are
forward-looking statements involving risks and uncertainties that
can cause actual results to differ materially from those in such
forward-looking statements. Potential risks and uncertainties
include, but are not limited to, the risks that the clinical trial
of DUR-928 in AH takes longer to conduct than anticipated due to
COVID-19 or other factors, the risk that clinical trials of
DUR-928, including AHFIRM, do not confirm the results from earlier
clinical or pre-clinical trials, or do not demonstrate the safety
or efficacy or the life saving potential of DUR-928 in a
statistically significant manner, risks that we or a third-party
licensee may not commercialize POSIMIR successfully, if at all, and
risks related to our ability to obtain capital to fund operations
and expenses. Further information regarding these and other risks
is included in DURECT's Form 10-K filed on March 5, 2021 under the heading "Risk
Factors."
NOTE: POSIMIR® and SABER® are trademarks
of DURECT Corporation. Other referenced trademarks belong to
their respective owners. DUR-928 is an investigational drug
candidate under development and has not been approved for
commercialization by the U.S. Food and Drug Administration or other
health authorities for any indication. Full prescribing information
for POSIMIR, including its Boxed Warning, can be found at
www.posimir.com.
View original
content:http://www.prnewswire.com/news-releases/durect-corporation-to-announce-first-quarter-2021-financial-results-and-provide-business-update-on-may-4-301277707.html
SOURCE DURECT Corporation